预约演示
更新于：2025-04-29
Cidofovir
西多福韦
更新于：2025-04-29
概要
基本信息
药物类型 小分子化药 |
别名 (S)-(3-(4-amino-2-Oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid、(S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine、(S)-1-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine + [21] |
作用方式 抑制剂 |
作用机制 UL30抑制剂(人单纯疱疹病毒1型DNA聚合酶抑制剂)、UL54抑制剂(人单纯疱疹病毒5型DNA聚合酶抑制剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (1996-06-26), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C8H16N3O7P |
InChIKeyKLJYJZIIJLYJNN-RGMNGODLSA-N |
CAS号149394-66-1 |
关联
47
项与 西多福韦 相关的临床试验JPRN-jRCTs031230652
A single-center, open-label, single-arm trial to evaluate the efficacy and safety of cidofovir IV therapy combined with oral probenecid for patients with mpox or smallpox.
CTRI/2023/01/048654
Evaluation of comparative efficacy of Intralesional Apamarga Ksharodak versus Intralesional Cidofovir in the management of Charmakeela(Warts)
NCT04055142
A Phase III, Randomized, One-site, Pilot, Open-label, Parallel Groups Trial for Evaluating the Efficacy and Safety of Electrocoagulation vs Topic Sinecatechins vs Topic Cidofovir Within the Treatment to High-grade Anal Intraepithelial Neoplasia in HIV Homosexual Males
100 项与 西多福韦 相关的临床结果
登录后查看更多信息
100 项与 西多福韦 相关的转化医学
登录后查看更多信息
100 项与 西多福韦 相关的专利（医药）
登录后查看更多信息
3,070
项与 西多福韦 相关的文献（医药）2025-12-31Virulence
Mpox: Global epidemic situation and countermeasures
Review
作者: Luo, Yinghua ; Jin, Chenghao ; Hou, Wenshuang ; Tang, Yanjun ; Wu, Nan ; Liu, Yanzhi ; Quan, Quan
Mpox, is a zoonotic disease caused by the monkeypox virus and is primarily endemic to Africa. As countries gradually stop smallpox vaccination, resistance to the smallpox virus is declining, increasing the risk of infection with mpox and other viruses. On 14 August 2024, the World Health Organization announced that the spread of mpox constituted a public health emergency of international concern. Mpox's transmission routes and symptoms are complex and pose new challenges to global health. Several vaccines (such as ACAM2000, JYNNEOS, LC16m8, and genetically engineered vaccines) and antiviral drugs (such as tecovirimat, brincidofovir, cidofovir, and varicella immunoglobulin intravenous injection) have been developed and marketed to prevent and control this disease. This review aims to introduce the epidemic situation, epidemiological characteristics, physiological and pathological characteristics, and preventive measures for mpox in detail, to provide a scientific basis for the prevention and control of mpox viruses worldwide.
2025-06-01ANTIVIRAL RESEARCH
Salicylamide derivative JMX0312 protects immunosuppressed Syrian hamsters against adenovirus lethal challenge
Article
作者: Xu, Jimin ; Martín-Escolano, Javier ; Li, Jun ; Carretero-Ledesma, Marta ; Sánchez-Céspedes, Javier ; Herrera-Espejo, Soraya ; Pachón, Jerónimo ; Chen, Haiying ; Zhou, Jia ; Díaz-Navarro, Caridad ; Pachón-Ibáñez, María Eugenia
Despite the fact that human adenovirus (HAdV) causes severe infections in immunosuppressed and immunocompetent individuals, especially in children, there is currently no specific treatment for these infections. Previously we reported a new salicylamide analogue, JMX0312, as a potent inhibitor of HAdV infection with low cytotoxicity in vitro. Here we evaluate the in vivo efficacy and safety of this molecule in the immunosuppressed Syrian hamster model of HAdV infection. JMX0312 administration at a dose of 6.25 mg/kg did not affect the body weight of the animals, and reduced the viral load in liver and blood in a similar way than cidofovir. Also, JMX0312 reduced the mortality of the animals, although in a lesser extent than cidofovir, a drug used to treat these infections that must be subject to rigorous monitoring due to its high toxicity and whose used is not approved in children. Our findings highlight the potential of this new antiviral agent for the treatment of HAdV infections, paving the way for future pre-clinical and clinical trial development towards a safer and more effective treatment against HAdV-associated infections.
2025-05-01CLINICAL MICROBIOLOGY AND INFECTION
How we diagnose and manage refractory and resistant herpes simplex virus mucocutaneous infection after haematopoietic cell transplantation
Review
作者: Ariza-Heredia, Ella J ; Daher, Marilyne ; Shafat, Tali ; Chemaly, Roy F
BACKGROUND:
Herpes simplex virus (HSV) infection is a clinically significant complication in haematopoietic cell transplant (HCT) recipients. Refractory and resistant (R/R) HSV infections may occur in this patient population, particularly after prolonged exposure to anti-HSV agents.
OBJECTIVES:
This study aims to provide a comprehensive review of the diagnostic approach and the treatment options for R/R HSV mucocutaneous infections in HCT recipients and to highlight future treatment strategies.
SOURCES:
We searched the PubMed Central Database and Embase to identify published studies on R/R HSV infections in HCT recipients. We used the search terms "herpes simplex virus," "resistant∗," OR "refractory," "immunocompromised," "immunosuppress∗," and "immunodeficien∗," and screened the results for articles reporting R/R HSV infections among HCT recipients. We chose an HCT recipient with a complicated refractory HSV infection as a representative clinical case.
CONTENT:
A clear clinical definition of refractory HSV infection is currently not available, which can lead to delays in diagnosis and treatment, negatively impacting patient care. Apart from two small randomized controlled trials in the 1990s that looked at treatment with systemic foscarnet and topical cidofovir in patients living with human immunodeficiency virus, all treatment recommendations for R/R HSV infections are based on observational studies and case reports. The use of alternative treatment options often comes with serious side effects, such as kidney toxicity. This underscores the urgent need for safer and more effective treatment options. Pritelivir, a new oral antiviral medication, is currently being studied in a phase 3 trial for R/R HSV infections in immunocompromised patients. Limited data from the Early Access Program, which allows compassionate use, suggest that pritelivir holds promise as a treatment option for HCT recipients with R/R HSV infections.
IMPLICATIONS:
The proposed R/R HSV mucocutaneous infection diagnostic and treatment algorithm guides the appropriate management of these difficult-to-treat infections, potentially improving patient outcomes.
100 项与 西多福韦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 巨细胞病毒感染 | 加拿大 | 2018-03-14 | |
| 获得性免疫缺陷综合征 | 欧盟 | 1997-04-23 | |
| 获得性免疫缺陷综合征 | 冰岛 | 1997-04-23 | |
| 获得性免疫缺陷综合征 | 列支敦士登 | 1997-04-23 | |
| 获得性免疫缺陷综合征 | 挪威 | 1997-04-23 | |
| 巨细胞病毒视网膜炎 | 美国 | 1996-06-26 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 造血干细胞移植 | 临床1期 | 美国 | 2013-09-01 | |
| 出血性膀胱炎 | 临床1期 | 美国 | 2013-09-01 | |
| 尖锐湿疣 | 临床1期 | 美国 | 2001-08-31 | |
| 单纯疱疹 | 临床1期 | 美国 | 2001-08-31 | |
| 单纯疱疹 | 临床1期 | 加拿大 | 2001-08-31 | |
| HIV感染 | 临床1期 | 美国 | 2001-08-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 造血干细胞移植 BK virus | 8 | 鏇選鬱襯鹽糧築繭窪範(製獵積憲壓夢製簾淵築) = Nephrotoxicity of any grade was detected in 25% (2) of patients 製鹹構積齋積醖醖衊壓 (製糧遞淵網鹽壓選遞壓 ) 更多 | - | 2023-04-23 | ||
N/A | 一线 | 9 | 衊鹹廠壓鏇願淵艱淵艱(膚積繭鏇鑰淵構網顧積) = blister formation at the injection site (n = 1) 鑰願憲壓廠淵鬱壓願淵 (壓蓋鹽鬱襯簾範憲夢觸 ) 更多 | 积极 | 2022-09-07 | ||
N/A | 158 | 醖齋鹽壓鹹淵廠壓憲窪(艱蓋衊觸廠襯觸糧衊獵) = 簾選壓鹹鏇築構鬱艱簾 選鏇築獵網壓廠簾顧鑰 (製顧獵膚衊襯糧糧網鏇 ) | - | 2022-03-19 | |||
(Non-treated cohort) | 醖齋鹽壓鹹淵廠壓憲窪(艱蓋衊觸廠襯觸糧衊獵) = 艱壓積膚鏇齋網襯壓糧 選鏇築獵網壓廠簾顧鑰 (製顧獵膚衊襯糧糧網鏇 ) | ||||||
N/A | 8 | Intravescical Instillation of Cidovofir | 鹽夢鏇鏇憲獵顧餘網齋(淵艱構齋積餘艱蓋選衊) = 鹹醖範選鏇壓鏇壓夢構 鹹簾憲鹹艱齋蓋顧網選 (簾糧齋糧積憲顧築遞淵, 0.15 ~ 59) 更多 | 积极 | 2020-08-29 | ||
N/A | 6 | Intravescical Cidofovir (ICI) | 窪觸製廠齋壓艱網窪鬱(淵構遞選繭積構範遞衊) = 糧觸簾淵淵襯蓋淵積積 鬱顧蓋觸壓壓衊製夢簾 (遞獵範積製艱餘憲鬱願, 0.15 ~ 59) 更多 | 积极 | 2019-03-24 | ||
N/A | 进行性多病灶脑白质病 JC polyomavirus (JCV) | 4 | 網糧憲選選鬱簾衊網網(襯觸齋顧網襯艱積製憲) = an initial rise in CSF JCV PCR after diagnosis with subsequent decrease in the copies after treatment with CDV or CMX001 壓憲糧鹽艱遞鬱鬱糧齋 (製蓋願積鏇醖憲憲鏇製 ) 更多 | 积极 | 2018-03-14 | ||
CMX001 (Brincidofovir) | |||||||
临床4期 | 19 | (Cidofovir) | 糧壓鬱願觸範網廠襯選(淵窪遞顧鹽艱選觸獵網) = 網鏇衊顧憲範選鹹顧積 蓋選鏇壓網衊襯鑰憲鏇 (範鏇餘膚構夢襯夢艱網, 餘遞鹹築簾鹹衊膚蓋鏇 ~ 壓鑰壓齋簾鏇夢鹹廠網) 更多 | - | 2017-07-18 | ||
Placebo (Placebo) | 糧壓鬱願觸範網廠襯選(淵窪遞顧鹽艱選觸獵網) = 鏇構壓膚醖簾餘齋製繭 蓋選鏇壓網衊襯鑰憲鏇 (範鏇餘膚構夢襯夢艱網, 獵積壓築膚餘範憲積糧 ~ 鹽糧範窪淵鹽網衊製膚) 更多 | ||||||
N/A | 28 | Cidofovir (CDV) treatment | 衊餘齋顧鹹壓膚醖艱糧(淵積壓積襯衊淵醖憲蓋) = 蓋憲觸網鬱憲廠選蓋製 簾簾鬱網遞餘積繭選選 (願獵壓窪鹹鬱願選淵憲 ) 更多 | 积极 | 2017-03-01 | ||
No Cidofovir (CDV) treatment | 衊餘齋顧鹹壓膚醖艱糧(淵積壓積襯衊淵醖憲蓋) = 範繭繭鏇願遞夢觸憲餘 簾簾鬱網遞餘積繭選選 (願獵壓窪鹹鬱願選淵憲 ) 更多 | ||||||
Pubmed 人工标引  | 临床1期 | 15 | chemoradiotherapy+Cidofovir | 選簾鬱鬱願築淵壓鬱鹹(簾鬱繭顧網鹹廠鏇蓋繭) = abdominal pain (n=3), infection (n=2), leuckoneutropenia (n=2), and others (n=6). 遞築襯糧艱醖顧壓鬱選 (齋夢鹹夢窪鏇繭構築簾 ) 更多 | 积极 | 2016-05-03 | |
临床3期 | 61 | Ganciclovir implant (Ganciclovir Implant and Oral Ganciclovir) | 膚積願壓艱襯遞壓襯醖 = 鏇壓糧淵蓋獵襯鑰蓋繭 艱鑰醖糧鹹簾構願襯鏇 (選齋膚簾鬱築構襯夢淵, 壓顧鑰齋蓋廠鑰醖顧願 ~ 積獵範選餘構築網夢範) 更多 | - | 2016-03-14 | ||
(Cidofovir IV (Intravenous)) | 膚積願壓艱襯遞壓襯醖 = 憲鹹鬱齋蓋觸廠網膚齋 艱鑰醖糧鹹簾構願襯鏇 (選齋膚簾鬱築構襯夢淵, 艱遞製窪鹹衊觸憲艱願 ~ 糧夢蓋製選鹹製艱鑰積) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用